Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
Healthcare
$7.38 -2.78%
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
52W Low $1.99High $5.32
Volume 1.41M
Average 2.42M
Income Statement
Follow revenue through to earnings.
Revenue
$185.74M
FY 2025 · Annual
-28.3% YoYOperating Income
-$6.74M
FY 2025 · Annual
Net Income
-$130.77M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 799.24M | 883M | 288.95M | 259.19M | 185.74M |
| Cost of Revenue | 140.56M | 168.96M | 148.74M | 150.88M | 152.35M |
| Gross Profit | 658.68M | 714.04M | 140.2M | 108.31M | 33.39M |
| Gross Margin | 82.4% | 80.9% | 48.5% | 41.8% | 18.0% |
| Research & Development | 15.22M | 18.37M | 17.28M | 19.22M | 23.33M |
| Selling, General & Admin | 100.06M | 129.26M | 151.39M | 161.77M | 171.47M |
| Operating Expenses | 104.03M | 139.83M | 171.85M | 343.93M | 40.13M |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| EBITDA | 585.78M | 609.99M | 712.41M | (156.92M) | (147.51M) |
| EBITDA Margin | 73.3% | 69.1% | 246.6% | -60.5% | -79.4% |
| Operating Income | 554.65M | 574.22M | (31.65M) | (235.62M) | (6.74M) |
| Operating Margin | 69.4% | 65.0% | -11.0% | -90.9% | -3.6% |
| Interest Income | 0 | 2.34M | 27.73M | 27.4M | 23.95M |
| Interest Expense | 30.26M | 20.41M | 45.89M | 47.7M | 26.99M |
| Other Income / Expenses | (23.88M) | (22.74M) | 649.38M | (25.87M) | (228.24M) |
| Income Before Tax | 530.77M | 551.47M | 617.74M | (261.48M) | (234.97M) |
| Pre-Tax Margin | 66.4% | 62.5% | 213.8% | -100.9% | -126.5% |
| Income Tax Expense | 61.52M | 60.81M | 756.11M | (1.86M) | (4.21M) |
| Net Income | 182.04M | 220.21M | (119.03M) | (144.85M) | (130.77M) |
| Net Margin | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| EPS (Basic) | 1.59 | 1.67 | (0.90) | (1.05) | (0.91) |
| EPS (Diluted) | 1.56 | 1.67 | (0.90) | (1.05) | (0.91) |
| 114.79M | 131.54M | 131.92M | 137.91M | 145.07M | |
| 121.97M | 131.7M | 131.92M | 137.91M | 145.07M |
MRVI Earnings Waterfall · TTM
NASDAQ:MRVI · Revenue to Net Income
Key Ratios
EPS$-0.54
Gross Margin32.4%
Net Margin-40.7%
P/E Ratio-13.6
P/S Ratio10.9
Analysis
$208.8M of revenue converted into -$77.4M of net income for the selected period. Gross margin is 32.4% and net margin is -40.7%, showing how much revenue survives after costs and taxes. EPS is $-0.54, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 9, 2026 |
How much revenue does MRVI generate?
Maravai LifeSciences Holdings, Inc. (MRVI) reported $185.74M of revenue in fiscal 2025.
Is MRVI profitable?
Maravai LifeSciences Holdings, Inc. (MRVI) reported -$130.77M of net income, with a net margin of -70.4%.
Continue the stock analysis
Jump to another research area for this company.